Back to Search
Start Over
Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology
- Source :
- Cardiovascular research, 115(1), 10-19. Oxford University Press, Cardiovascular Research, Vol. 115, No 1 (2019) pp. 10-19, CARDIOVASCULAR RESEARCH, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Cardiovascular Research
- Publication Year :
- 2019
-
Abstract
- Dysregulated lipid metabolism induces an inflammatory and immune response leading to atherosclerosis. Conversely, inflammation may alter lipid metabolism. Recent treatment strategies in secondary prevention of atherosclerosis support beneficial effects of both anti-inflammatory and lipid-lowering therapies beyond current targets. There is a controversy about the possibility that anti-inflammatory effects of lipid-lowering therapy may be either independent or not of a decrease in low-density lipoprotein cholesterol. In this Position Paper, we critically interpret and integrate the results obtained in both experimental and clinical studies on anti-inflammatory actions of lipid-lowering therapy and the mechanisms involved. We highlight that: (i) besides decreasing cholesterol through different mechanisms, most lipid-lowering therapies share anti-inflammatory and immunomodulatory properties, and the anti-inflammatory response to lipid-lowering may be relevant to predict the effect of treatment, (ii) using surrogates for both lipid metabolism and inflammation as biomarkers or vascular inflammation imaging in future studies may contribute to a better understanding of the relative importance of different mechanisms of action, and (iii) comparative studies of further lipid lowering, anti-inflammation and a combination of both are crucial to identify effects that are specific or shared for each treatment strategy.
- Subjects :
- 0301 basic medicine
Physiology
Anti-Inflammatory Agents
030204 cardiovascular system & hematology
ddc:616.07
Bioinformatics
PCSK9
11459 Center for Molecular Cardiology
PCSK9 Gene
chemistry.chemical_compound
0302 clinical medicine
2737 Physiology (medical)
Risk Factors
Medicine
Hypolipidemic Agents
PCSK9 Inhibitors
Position Paper from European Society of Cardiology Working Group
Lipids
3. Good health
Treatment Outcome
10209 Clinic for Cardiology
lipids (amino acids, peptides, and proteins)
Inflammation Mediators
Proprotein Convertase 9
medicine.symptom
Cardiology and Cardiovascular Medicine
Serine Proteinase Inhibitors
Inflammation
610 Medicine & health
Lipid-lowering therapy
2705 Cardiology and Cardiovascular Medicine
03 medical and health sciences
Immune system
Physiology (medical)
Animals
Humans
Immune response
Dyslipidemias
business.industry
Cholesterol
Statins
Lipid metabolism
1314 Physiology
Atherosclerosis
030104 developmental biology
chemistry
Position paper
business
Biomarkers
Subjects
Details
- Language :
- English
- ISSN :
- 00086363
- Database :
- OpenAIRE
- Journal :
- Cardiovascular research, 115(1), 10-19. Oxford University Press, Cardiovascular Research, Vol. 115, No 1 (2019) pp. 10-19, CARDIOVASCULAR RESEARCH, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Cardiovascular Research
- Accession number :
- edsair.doi.dedup.....bfeaab21c9b64405f549c7c8fd3d0a38